Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neuropathol Exp Neurol ; 72(10): 933-41, 2013 Oct.
Article in English | MEDLINE | ID: mdl-24042196

ABSTRACT

The scaffold protein A-kinase anchor protein 12 (AKAP12) exerts tumor suppressor activity and is downregulated in several tumor entities. We characterized AKAP12 expression and regulation in astrocytomas, including pilocytic and diffusely infiltrating astrocytomas. We examined 194 human gliomas and 23 normal brain white matter samples by immunohistochemistry or immunoblotting for AKAP12 expression. We further performed quantitative methylation analysis of the AKAP12 promoter by MassARRAY® of normal brain, World Health Organization (WHO) grade I to IV astrocytomas, and glioma cell lines. Our results show that AKAP12 is expressed in a perivascular distribution in normal CNS, strongly upregulated in tumor cells in pilocytic astrocytomas, and weakly expressed in diffuse astrocytomas of WHO grade II to IV. Methylation analyses revealed specific hypermethylation of AKAP12α promoter in WHO grade II to IV astrocytomas. Restoration experiments using 5-aza-2'-deoxycytidine in primary glioblastoma cells decreased AKAP12α promoter methylation and markedly increased AKAP12α mRNA levels. In summary, we demonstrate that AKAP12 is differentially expressed in human astrocytomas showing high expression in pilocytic but low expression in diffuse astrocytomas of all WHO-grades. Our results further indicate that epigenetic mechanisms are involved in silencing AKAP12 in diffuse astrocytomas; however, a tumor suppressive role of AKAP12 in distinct astrocytoma subtypes remains to be determined.


Subject(s)
A Kinase Anchor Proteins/genetics , Astrocytoma/genetics , Brain Neoplasms/genetics , Cell Cycle Proteins/genetics , Gene Expression Regulation, Neoplastic , Promoter Regions, Genetic , A Kinase Anchor Proteins/metabolism , Adolescent , Adult , Aged , Aged, 80 and over , Astrocytoma/metabolism , Astrocytoma/pathology , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Cell Cycle Proteins/metabolism , Child , Child, Preschool , DNA Methylation , Female , Humans , Infant , Male , Middle Aged , Neoplasm Grading , Up-Regulation
2.
Acta Neuropathol ; 124(1): 83-97, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22249620

ABSTRACT

Glioblastoma (GBM), the most common malignant brain tumor, is among the most lethal neoplasms, with a median survival of approximately 1 year. Prognosis is poor since GBMs possess a strong migratory and highly invasive potential, making complete surgical resection impossible. Reduced expression of carboxypeptidase E (CPE), a neuropeptide-processing enzyme, in a cell death-resistant glioma cell line and lower CPE expression levels in the cohort of GBM samples of The Cancer Genome Atlas compared to normal brain control specimens prompted us to analyze the function of CPE as a putative tumor suppressor gene. In our samples, CPE was also reduced in GBM compared to normal brain with the strongest loss in cells surrounding hypoxic tumor areas as well as in most glioma cell lines and primary glioma cells. In our cohort of glioma patients, loss of CPE predominantly occurred in glioblastomas and was associated with worse prognosis. In glioma cells, CPE overexpression was significantly reduced, whereas knockdown or inhibition enhanced glioma cell migration and invasion. The decreased migratory potential following CPE overexpression was paralleled by altered cellular morphology, promoting a transition to focal adhesions and associated stress fibers. In contrast to the decreased migration, high CPE levels were associated with higher proliferative rates. As microenvironmental regulation cues, we identified CPE as being downregulated upon hypoxia or glucose deprivation. Our findings indicate an oxygen- and nutrition-dependent anti-migratory, but pro-proliferative role of CPE in gliomas with prognostic impact for patient survival, thereby contributing to the understanding of the "go or grow" hypothesis in gliomas.


Subject(s)
Brain Neoplasms/enzymology , Carboxypeptidase H/metabolism , Gene Expression Regulation, Neoplastic/physiology , Glioma/enzymology , Stress, Physiological/physiology , Animals , Brain Neoplasms/mortality , Brain Neoplasms/pathology , Carbocyanines/metabolism , Carboxypeptidase H/genetics , Cell Adhesion/drug effects , Cell Hypoxia/drug effects , Cell Hypoxia/physiology , Cell Line, Tumor , Cell Movement/drug effects , Cell Movement/physiology , Cell Proliferation , Disease Models, Animal , Gene Expression Regulation, Neoplastic/drug effects , Glial Fibrillary Acidic Protein/metabolism , Glioma/mortality , Glioma/pathology , Glucose/deficiency , Humans , Mice , Mice, Inbred C57BL , Neoplasm Invasiveness/genetics , RNA, Messenger/metabolism , RNA, Small Interfering/pharmacology , Stress, Physiological/drug effects , Succinates/pharmacology , Survival Analysis , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...